PAYNE JOHN BERNARD 4
4 · Zivo Bioscience, Inc. · Filed Jun 6, 2024
Insider Transaction Report
Form 4
PAYNE JOHN BERNARD
DirectorPresident and CEO
Transactions
- Disposition to Issuer
Nonstatutory Stock Option to Purchase Common Stock
2024-06-05−31,836→ 0 totalExercise: $17.16Exp: 2032-12-15→ Common Stock (31,836 underlying) - Disposition to Issuer
Nonstatutory Stock Option to Purchase Common Stock
2024-06-05−32,000→ 0 totalExercise: $33.00Exp: 2031-10-20→ Common Stock (32,000 underlying) - Disposition to Issuer
Nonstatutory Stock Option to Purchase Common Stock
2024-06-05−1,902→ 0 totalExercise: $26.88Exp: 2031-10-11→ Common Stock (1,902 underlying) - Award
Nonstatutory Stock Option to Purchase Common Stock
2024-06-05+167,180→ 167,180 totalExercise: $7.96Exp: 2034-06-04→ Common Stock (167,180 underlying) - Award
Nonstatutory Stock Option to Purchase Common Stock
2024-06-05+50,251→ 50,251 totalExercise: $7.96Exp: 2034-06-04→ Common Stock (50,251 underlying)
Footnotes (4)
- [F1]The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023.
- [F2]The canceled options were fully vested.
- [F3]The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96.
- [F4]The option was issued pursuant to the 2021 Equity Incentive Plan and all options vested immediately upon the date of acceptance of grant.